A phase i open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 1, 2013, Pages 19-27

  Ellis, Peter M ^a   Chu, Quincy S ^b   Leighl, Natasha ^c   Laurie, Scott A ^d   Fritsch, Holger ^e   Gaschler Markefski, Birgit ^e   Gyorffy, Steve ^f   Munzert, Gerd ^f  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Chemotherapy; Non small cell lung cancer; Phase I; Polo like kinase 1 inhibitors

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; PEMETREXED;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INJECTION SITE REACTION; LACRIMATION; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PRURITUS; SIDE EFFECT; SORE THROAT; STOMATITIS; VOMITING;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; FATIGUE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PRURITUS; PTERIDINES; TREATMENT OUTCOME;

EID: 84870567659     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.04.003     Document Type: Article

References (26)

1. F.A. Shepherd, J. Dancey, R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
2. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
3. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
4. T.A. Yap, L.R. Molife, S.P. Blagden Targeting cell cycle kinases and kinesins in anticancer drug development Expert Opin Drugs Discov 2 2007 539 560
5. M. Petronczki, P. Lénárt, J.M. Peters Polo on the rise-from mitotic entry to cytokinesis with Plk1 Dev Cell 14 2008 646 659
6. M. Raab, S. Kappel, A. Krämer Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells Nat Commun 2 2011 395
7. J.R. Jackson, D.R. Patrick, M.M. Dar Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7 2007 107 117
8. F. Eckerdt, J. Yuan, K. Strebhardt Polo-like kinases and oncogenesis Oncogene 24 2005 267 276
9. U. Holtrich, G. Wolf, A. Bräuninger Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors Proc Natl Acad Sci U S A 91 1994 1736 1740
10. K. Strebhardt, A. Ullrich Targeting polo-like kinase 1 for cancer therapy Nat Rev Cancer 6 2006 321 330
11. G. Wolf, R. Elez, A. Doermer Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer Oncogene 14 1997 543 549
12. M. Steegmaier, M. Hoffmann, A. Baum BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr Biol 1 2007 316 322
13. P. Lénárt, M. Petronczki, M. Steegmaier The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 Curr Biol 17 2007 304 315
14. K. Mross, A. Frost, S. Steinbild Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors J Clin Oncol 26 2008 5511 5517
15. R.D. Hofheinz, S.E. Al-Batran, A. Hochhaus An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors Clin Cancer Res 16 2010 4666 4674
16. A. Frost, K. Mross, S. Steinbild Phase I study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours Curr Oncol 19 2012 e28 e35
17. M. Sebastian, M. Reck, C.F. Waller The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial J Thorac Oncol 5 2010 1060 1067
18. A. Baum, U. Gürtler, G. Munzert In vivo efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in combination with various cytotoxic agents Eur J Cancer Suppl 4 2006 110 111
19. A. Baum, P. Garin-Chesa, U. Gürtler Efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in models of human non-small cell lung carcinoma J Thorac Oncol 2 2007 S435
20. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. A. Hughes, P. Calvert, A. Azzabi Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma J Clin Oncol 20 2002 3533 3544
22. C.J. Sweeney, C.H. Takimoto, J.E. Latz Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer Clin Cancer Res 12 2006 536 542
23. D.A. Rinaldi, J.G. Kuhn, H.A. Burris A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation Cancer Chemother Pharmacol 44 1999 372 380
24. G.K. Dy, A. Suri, J.M. Reid A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors Cancer Chemother Pharmacol 55 2005 522 530
25. S. Sur, R. Pagliarini, F. Bunz A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 Proc Natl Acad Sci U S A 106 2009 3964 3969
26. P. Schoffski, A. Awada, H. Dumez A phase I single dose escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours Eur J Cancer 6 2008 abstract 36